- Home
- ENVB
as 02-21-2025 4:00pm EST
Enveric Biosciences Inc is a biotechnology company dedicated to the development of novel neuroplastogenic small-molecule therapeutics for the treatment of depression, anxiety, and addiction disorders. The company's lead program, EB-003, is a first-in-class approach to the treatment of difficult-to-address mental health disorders designed to promote neuroplasticity without inducing hallucinations in the patient. Enveric is also developing EB-002, formerly EB-373, a next-generation synthetic prodrug of the active metabolite, psilocin, being studied as a treatment of psychiatric disorders.
| Founded: | 1994 | Country: | United States |
| Employees: | N/A | City: | NAPLES |
| Market Cap: | 3.3M | IPO Year: | N/A |
| Target Price: | N/A | AVG Volume (30 days): | 564.4K |
| Analyst Decision: | N/A | Number of Analysts: | N/A |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -26.17 | EPS Growth: | N/A |
| 52 Week Low/High: | $1.26 - $657.00 | Next Earning Date: | 03-25-2025 |
| Revenue: | N/A | Revenue Growth: | N/A |
| Revenue Growth (this year): | N/A | Revenue Growth (next year): | N/A |
Latest Enveric Biosciences Inc. News
ENVB Breaking Stock News: Dive into ENVB Ticker-Specific Updates for Smart Investing
Business Wire
19 days ago
Enveric Biosciences and Restoration Biologics Announce Licensing Agreements to Treat Joint Disease
Business Wire
19 days ago
Enveric Biosciences Announces Closing of $5 Million Public Offering
GuruFocus.com
23 days ago
Enveric Biosciences Prices $5 Million Public Offering; Shares Drop 40% in Premarket Trading
Business Wire
23 days ago
Enveric Biosciences Announces Pricing of $5 Million Public Offering
Business Wire
23 days ago
Enveric Biosciences Receives Notice of Allowance for Lead Drug Candidate EB-003 from United States Patent and Trademark Office
Business Wire
2 months ago
Enveric Biosciences to Present at and Participate in Panel Discussion at Sachs Associates 8th Annual Neuroscience Innovation Forum During "J.P. Morgan Week 2025"
Business Wire
3 months ago
Enveric Biosciences Announces New U.S. Patents Supporting EVM301 Series and EVM201 Series Compounds
Business Wire
3 months ago
Enveric Biosciences Preclinical Pharmacokinetic Studies of EB-003 Support Oral Bioavailability, Demonstrate Brain Penetration, and Show No Evidence of Hallucination-like Behavior
Compare ENVB vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "ENVB Enveric Biosciences Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.